Esperion Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Esperion Therapeutics (ESPR) Tops Q4 EPS by 50c
February 22, 2022 7:14 AM ESTEsperion Therapeutics (NASDAQ: ESPR) reported Q4 EPS of ($1.77), $0.50 better than the analyst estimate of ($2.27). Revenue for the quarter came in at $15.4 million versus the consensus estimate of $14.48 million.
2022 Financial Outlook:
Research and Development expenses for the full year 2022 are expected to be... More
